Molbio Diagnostics Limited (NSE:MOLBIO)
1,094.75
-49.40 (-4.32%)
Aug 28, 2026, 3:29 PM IST
Molbio Diagnostics Cash Flow Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Operating Activities
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 |
Net Income | 1,666 | 1,451 | 1,020 | -7.26 |
Depreciation & Amortization | 625.81 | 432.36 | 395.45 | 312.41 |
Other Amortization | 10.59 | 13.17 | 14.63 | 4.81 |
Loss (Gain) From Sale of Assets | 3.94 | 0.63 | -3.66 | 0.44 |
Asset Writedown & Restructuring Costs | - | 35.16 | 263.59 | 9.78 |
Loss (Gain) From Sale of Investments | - | - | 0.02 | - |
Loss (Gain) on Equity Investments | 21.98 | 19.7 | 0.17 | - |
Provision & Write-off of Bad Debts | 134.98 | 155.96 | 379.03 | 7.12 |
Other Operating Activities | 358.2 | -55.62 | 227.91 | -238.15 |
Change in Accounts Receivable | -1,461 | 1,372 | -2,639 | 634.17 |
Change in Inventory | -283.22 | -1,341 | 150.13 | -319.79 |
Change in Accounts Payable | 250.46 | 1,365 | 321 | 353.56 |
Change in Other Net Operating Assets | -824.3 | -577.7 | -32.62 | -115.77 |
Operating Cash Flow | 503.85 | 2,871 | 95.7 | 641.32 |
Operating Cash Flow Growth | -82.45% | 2900.03% | -85.08% | - |
Investing Activities
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 |
Capital Expenditures | -500.22 | -546.61 | -263.68 | -144.98 |
Sale of Property, Plant & Equipment | 4.29 | 0.55 | - | 0.25 |
Cash Acquisitions | - | - | - | -390.29 |
Sale (Purchase) of Real Estate | - | - | -271.69 | - |
Investment in Securities | -483.73 | -610.07 | 78.52 | -83 |
Other Investing Activities | 47.44 | -70.4 | 8.9 | 213.36 |
Investing Cash Flow | -932.22 | -1,227 | -450.1 | -397.32 |
Financing Activities
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 |
Short-Term Debt Issued | 979.74 | 0.38 | - | - |
Long-Term Debt Issued | 2,248 | 27.48 | 269.11 | 14.56 |
Total Debt Issued | 3,227 | 27.86 | 269.11 | 14.56 |
Short-Term Debt Repaid | - | - | -416.96 | -149.64 |
Long-Term Debt Repaid | -192.65 | -166.38 | -77.05 | -40.11 |
Total Debt Repaid | -192.65 | -166.38 | -494.01 | -189.75 |
Net Debt Issued (Repaid) | 3,035 | -138.52 | -224.9 | -175.19 |
Issuance of Common Stock | - | - | - | 400.01 |
Other Financing Activities | -274.13 | -122.95 | -90.63 | -42.39 |
Financing Cash Flow | 2,761 | -261.47 | -315.53 | 182.43 |
Net Cash Flow
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 |
Foreign Exchange Rate Adjustments | 148.18 | - | - | - |
Miscellaneous Cash Flow Adjustments | 244.94 | - | - | - |
Net Cash Flow | 2,725 | 1,383 | -669.93 | 426.43 |
Free Cash Flow
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 |
Free Cash Flow | 3.63 | 2,324 | -167.98 | 496.34 |
Free Cash Flow Growth | -99.84% | - | - | - |
Free Cash Flow Margin | 0.03% | 22.78% | -2.01% | 14.93% |
Free Cash Flow Per Share | 0.03 | 20.61 | -1.49 | 4.41 |
Levered Free Cash Flow | -239.8 | 2,589 | -319.5 | - |
Unlevered Free Cash Flow | -43.59 | 2,689 | -233.94 | - |
Additional Metrics
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 |
Cash Interest Paid | 274.13 | 129.45 | 121.8 | 42.39 |
Cash Income Tax Paid | 706.83 | 798.66 | 434.65 | 381.44 |
Change in Working Capital | -2,318 | 818.64 | -2,201 | 552.17 |